Evidence map›Paper›PMID 40219553›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2025

[Biological activity and antitumor effect of long-acting recombinant human interleukin-2 drug].

Xuejun Liang, Fengxia Zhang, Ting Jin, Jingjing Zhu

Abstract readEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xuejun LiangNovocodex Biopharmaceuticals Company Limited, Shaoxing 312000, Zhejiang, China.
Fengxia ZhangNovocodex Biopharmaceuticals Company Limited, Shaoxing 312000, Zhejiang, China.
Ting JinNovocodex Biopharmaceuticals Company Limited, Shaoxing 312000, Zhejiang, China.
Jingjing ZhuNovocodex Biopharmaceuticals Company Limited, Shaoxing 312000, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the biological activity and antitumor effect of pegylated recombinant human interleukin 2 (PEG-rhIL-2) obtained by site-specific conjugation of polyethylene glycol (PEG) with non-natural amino acids, and to explore its antitumor mechanism.

methodsThe binding activities of PEG-rhIL-2 at three different sites (T41, Y45, and V91) to human interleukin 2 receptors α (IL-2R

resultsThe SPR detection results showed that the binding activities of PEG-rhIL-2 to IL-2R

conclusionY45-PEG-rhIL-2 obtained by site-specific conjugation

Indexed as

Antineoplastic AgentsInterleukin-2AnimalsCell Line, TumorHumansInterleukin-2 Receptor alpha SubunitInterleukin-2 Receptor beta SubunitMicePolyethylene GlycolsRecombinant ProteinsSignal TransductionSTAT5 Transcription FactorAntineoplastic AgentsInterleukin-2Interleukin-2 Receptor alpha SubunitInterleukin-2 Receptor beta SubunitPolyethylene GlycolsRecombinant ProteinsSTAT5 Transcription FactorImmunotherapyNon-natural amino acidsRecombinant interleukin 2

Identifiers

PMID40219553
PMCPMC11992458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.